|Bid||0.00 x 900|
|Ask||6.00 x 1400|
|Day's Range||5.25 - 5.40|
|52 Week Range||1.67 - 6.84|
|Beta (3Y Monthly)||1.55|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
On May 9th VolitionRx (VNRX) reported financial results for their fiscal 2019 first quarter ending March 31st. The study will include 1,200 participants receiving low-dose CT scan, 1,000 of which have lung cancer.
On a per-share basis, the Singapore-based company said it had a loss of 12 cents. In the final minutes of trading on Wednesday, the company's shares hit $3.36. A year ago, they were trading at $2.41. _____ ...
Following reporting of Q4 earnings in mid-March, VolitionRx (VNRX) had a spate of news leading up to their ‘Capital Markets Day on April 9th at the New York Stock Exchange. The news is an extension of the product development related updates provided during the Q4 earnings call, which as a reminder, included new (i.e.
VolitionRx Limited's (NYSEMKT:VNRX): VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. On 31 December 2018, the US$128m market-cap pos...
VolitionRx (VNRX) reported Q4 financial results and provided a business update. Timelines have been regularly delayed as the clinical grade assays work their way through the ‘product grade’ validation processes and studies.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companiesRead More...